Calidi Biotherapeutics Inc (CLDI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,462 | -25,427 | -17,671 | 5,623 | 1,462 |
| Depreciation Amortization | 384 | 376 | 175 | N/A | N/A |
| Accounts payable and accrued liabilities | 21 | 1,624 | 1,562 | -1 | -2 |
| Other Working Capital | 10 | 3,569 | 3,878 | 157 | 64 |
| Other Operating Activity | 2,940 | 6,644 | 2,718 | -6,513 | -1,989 |
| Operating Cash Flow | $-3,107 | $-13,214 | $-9,338 | $-734 | $-465 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -137 | -428 | -267 | N/A | N/A |
| Other Investing Activity | 0 | -66 | -66 | 0 | 0 |
| Investing Cash Flow | $-137 | $-494 | $-333 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 750 | 500 | N/A | N/A | N/A |
| Debt Issued | N/A | 1,000 | N/A | N/A | N/A |
| Debt Repayment | -19 | -81 | -58 | N/A | N/A |
| Common Stock Issued | 181 | 114 | 114 | N/A | N/A |
| Other Financing Activity | 2,879 | 10,554 | 7,712 | 0 | 0 |
| Financing Cash Flow | $3,791 | $12,087 | $7,768 | $N/A | $N/A |
| Exchange Rate Effect | N/A | -26 | -34 | N/A | N/A |
| Beginning Cash Position | 590 | 2,237 | 2,237 | 1,063 | 1,063 |
| End Cash Position | 1,137 | 590 | 300 | 329 | 598 |
| Net Cash Flow | $547 | $-1,647 | $-1,937 | $-734 | $-465 |
| Free Cash Flow | |||||
| Operating Cash Flow | -3,107 | -13,214 | -9,338 | -734 | -465 |
| Capital Expenditure | -137 | -428 | -267 | N/A | N/A |
| Free Cash Flow | -3,244 | -13,642 | -9,605 | -734 | -465 |